We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Two FDA advisory committees have voted to allow an indwelling central venous access device in clinical trials after hearing please from parents of subjects as well as clinical investigators and sponsors. Read More
The FDA could significantly improve clinical trial design and boost investment in Alzheimer’s research and treatment, if it required applicants to meet one endpoint in clinical trials of drugs for Alzheimer’s disease, according to an Alzheimer’s research advocacy group. Read More
The FDA provides all the GCP regulations and guidances you need to run a clinical trial, but those documents can’t answer every question you may have. Fortunately, the agency offers another resource—the staff of its Office of Good Clinical Practices (OGCP). Every day, OGCP fields questions from investigators, sponsors, IRBs and other interested parties. Here are FDA’s answers to a couple of those questions. Read More
Cutting the costs of clinical trials, developing tools to improve clinical trial enrollment and filling gaps in antibacterial drug development were named as major priorities in the FDA’s fiscal 2018 budget proposal. Read More
The FDA’s Office of Regulatory Affairs officially began its transition to a program-based structure May 15, including a new Office of Bioresearch Monitoring Operations that will work with each of the FDA’s product centers to ensure subject protection in clinical studies. Read More
The Australian Therapeutic Goods Administration issued an industry guidance proposing to quickly approve certain types of low-risk variations to registered medicines without requiring evaluation, allowing sponsors to implement the changes immediately. Read More
Two-thirds of the way through fiscal year 2017, the FDA has received at least 877 ANDAs, passing fiscal 2016’s total of 852 and beating fiscal 2015’s total by more than 330 applications. Read More
The European Medicines Agency has decided to postpone the implementation of its Clinical Trials Regulation from October of next year to 2019 at the earliest, due to technical difficulties. Read More
Nevada’s landmark plan requiring insulin manufacturers to disclose price information was signed into law last week, establishing a more targeted strategy compared to the broader price transparency legislation currently being pursued in other states. Read More